MBX Biosciences names Steve Hoerter CEO, replacing Kent Hawryluk

MBX•2026-07-13

Leadership changes take effect immediately

MBX Biosciences named Executive Chairman Steve Hoerter chairman and CEO, replacing co-founder Kent Hawryluk, who stepped down as president, CEO and director.

Hoerter joined the board in April 2025 and became executive chairman in November 2025. He previously led Deciphera Pharmaceuticals through its commercial buildout.

Interim CFO John Smither was appointed CFO. He joined in March 2026 and previously served as CFO of Arcutis Biotherapeutics.

The changes took effect immediately as the company targets key second-half 2026 pipeline milestones, including a Phase 3 start for canvuparatide.

MBX Biosciences names Steve Hoerter CEO, replacing Kent Hawryluk

Leadership changes take effect immediately

Related News

Trump says US attacking Iran capabilities related to Strait of Hormuz

Nixxy files Form 3 initial beneficial ownership statement for director Simon Paul Colm Kearney

Trump exempts certain chemical companies from Biden-era emissions rules

Zoom CFO Michelle Chang disposes of Zoom common shares worth $1.51 million

Sable Offshore changes auditor to CohnReznick after Ham, Langston and Brezina resigns